Biotech

Inside the discoveries, personalities, and deals driving drug development. Sign up for the Readout newsletter here.

Celgene
Biotech

After its own megamerger, Celgene signs deals with two biotechs for their cancer drugs

By Jonathan Saltzman — Boston Globe

Pancreatic Cancer Cells
Biotech

Tyme Technologies misleads with new data on pancreatic cancer drug

By Matthew Herper

Close-up eye
Biotech

This small Canadian drug maker is taking on Allergan and its best-selling eye drop medicine

By Adam Feuerstein

FDA
Biotech

FDA rejects Immunomedics breast cancer drug, extending long regulatory drought

By Adam Feuerstein

The Readout LOUD

LISTEN: FDA furloughs, ’80s pop radio, and video game therapeutics

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Adam's Take

Lipocine fatty liver drug study results don’t hold up to scrutiny

By Adam Feuerstein

Eli Lilly
Business

Eli Lilly arranged for surprise purchase of Loxo, as the biotech pressed potential of its experimental drug

By Matthew Herper

Triple-negative breast cancer
Biotech

After 37 years of trying, this biotech nears a first drug approval in breast cancer

By Adam Feuerstein

IV Drip
In the Lab

New study points to best way to assess which cancer patients immunotherapy will help

By Sharon Begley

Live Chat

Archive online chat: The week in biotech, JPM, and beyond

By Adam Feuerstein, Rebecca Robbins, and Matthew Herper

Sanofi Genzyme Boston
Biotech

Sanofi-Genzyme inappropriately sought confidential patient information, suit alleges

By Kate Sheridan

The Readout LOUD

LISTEN: A people’s history of J.P. Morgan

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Len Schleifer
Pharma

Regeneron CEO: ‘We need a carrot-and-stick system’ to balance pricing and innovation

By Ed Silverman and Matthew Herper

Baby biotech goes to JPM
Biotech

For tiny biotechs, J.P. Morgan is a big opportunity — and a big cost

By Kate Sheridan

China's Kendall Square
Biotech

Chinese biotech was big at JPM. Attendees were enthusiastic — and wary

By Rebecca Robbins

JPM 2019 - Painted Ladies
Adam's Take

Amarin’s CEO drops enough JPM19 hints to know Vascepa sales driving higher

By Adam Feuerstein

Merck logo
Biotech

Merck: There’s more to us than Keytruda. Really

By Matthew Herper

JPM 2019 - Painted Ladies
Go West

Where’s Big Tech at biopharma’s big bash?

By Rebecca Robbins

Gottlieb Generic Drugs
Biotech

Shutdown has Aimmune waiting on FDA on multiple fronts — a sign of broader delays for biopharma

By Adam Feuerstein

Pharmalot

Pharmalittle: Allergan CEO says ‘social contract’ intact; medical marketing skyrockets to $30 billion

By Elizabeth Cooney

Biotech

With its stock in a slump, Moderna makes the case for its big-money valuation

By Damian Garde

Pharmalot

Pharmalittle: Existing drugs driving higher prices; Baselga lands at AstraZeneca

By Elizabeth Cooney

Nelson Vergel
Health

‘Left behind’: Drug companies and researchers have overlooked patients who don’t respond to HIV meds

By Apoorva Mandavilli

JPM 2019 - Painted Ladies
Adam's Take

It’s day one at JPM19. Here’s what we heard and learned

By Adam Feuerstein

A photo of Scott Gottlieb
Biotech

FDA plans to create a new office to leverage cutting-edge science

By Matthew Herper

Biotech

Sanofi to exit immuno-oncology collaboration with Regeneron

By Kate Sheridan

Pharmalot

Pharmalittle: Lilly makes a huge bet on Loxo; what about the Michaels?

By Elizabeth Cooney and Ed Silverman

Postpartum depression
Biotech

Sage Therapeutics pill improves postpartum depression in pivotal clinical trial

By Adam Feuerstein

Lung Cancer Cell
Biotech

Eli Lilly to buy Loxo Oncology for $8 billion in huge bet on cancer genetics

By Matthew Herper

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy